Consolidated statement of cash flows
January 1 to December 31, € in millions |
|
|
2025 |
|
2024 restated1 |
|
2024 previous |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities |
|
|
|
|
|
|
|
|
||||
Operating activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Net income from continuing operations |
|
|
|
1,606 |
|
1,152 |
|
867 |
||||
Adjustments to reconcile net income from continuing operations to cash and cash equivalents provided by operating activities |
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
18, 19, 20, 21, 34 |
|
1,120 |
|
1,239 |
|
1,204 |
||||
Change in deferred taxes |
|
11 |
|
-23 |
|
43 |
|
33 |
||||
Gain on sale of fixed assets and of investments and divestitures |
|
2 |
|
-166 |
|
-1 |
|
-1 |
||||
Gain from the investments accounted for |
|
|
|
-198 |
|
-38 |
|
-38 |
||||
Changes in assets and liabilities, net of amounts |
|
|
|
|
|
|
|
|
||||
Trade accounts and other receivables |
|
16 |
|
-220 |
|
43 |
|
21 |
||||
Inventories |
|
17 |
|
-210 |
|
-67 |
|
-55 |
||||
Other current and non-current assets |
|
18, 19 |
|
-149 |
|
95 |
|
229 |
||||
Accounts receivable from / payable to related parties |
|
|
|
15 |
|
-90 |
|
-54 |
||||
Trade accounts payable, provisions and |
|
23, 24, 25 |
|
756 |
|
51 |
|
146 |
||||
Income tax liabilities |
|
|
|
75 |
|
47 |
|
49 |
||||
Net cash provided by operating activities – continuing operations |
|
|
|
2,606 |
|
2,474 |
|
2,401 |
||||
Net cash used in/provided by operating activities – discontinued operations |
|
|
|
-32 |
|
-27 |
|
46 |
||||
Net cash provided by operating activities |
|
|
|
2,574 |
|
2,447 |
|
2,447 |
||||
Investing activities |
|
|
|
|
|
|
|
|
||||
Investing activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Purchases of property, plant and equipment and capitalized development costs |
|
20 |
|
-1,105 |
|
-980 |
|
-923 |
||||
Proceeds from subsidies to finance hospital-related property, plant and equipment |
|
|
|
119 |
|
57 |
|
– |
||||
Proceeds from sales of property, plant and equipment |
|
|
|
173 |
|
7 |
|
7 |
||||
Acquisitions and investments |
|
2, 37 |
|
-392 |
|
-80 |
|
-80 |
||||
Proceeds from sale of investments and divestitures |
|
2, 37 |
|
620 |
|
269 |
|
394 |
||||
Dividends received from Fresenius Medical Care |
|
|
|
121 |
|
112 |
|
112 |
||||
Net cash used in investing activities – continuing operations |
|
|
|
-464 |
|
-615 |
|
-490 |
||||
Net cash used in/provided by investing activities – discontinued operations |
|
|
|
-351 |
|
105 |
|
-20 |
||||
Net cash used in investing activities |
|
|
|
-815 |
|
-510 |
|
-510 |
||||
Financing activities |
|
|
|
|
|
|
|
|
||||
Financing activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Proceeds from short-term debt |
|
26 |
|
91 |
|
52 |
|
52 |
||||
Repayments of short-term debt |
|
26 |
|
-103 |
|
-496 |
|
-496 |
||||
Proceeds from long-term debt |
|
26 |
|
411 |
|
10 |
|
10 |
||||
Repayments of long-term debt |
|
26 |
|
-1,318 |
|
-602 |
|
-546 |
||||
Repayments of lease liabilities |
|
34 |
|
-173 |
|
-180 |
|
-181 |
||||
Proceeds from the issuance of bonds |
|
27 |
|
1,000 |
|
240 |
|
240 |
||||
Repayments of liabilities from bonds |
|
27 |
|
-2,250 |
|
-700 |
|
-700 |
||||
Proceeds from the issuance of the exchangeable bond |
|
28 |
|
609 |
|
– |
|
– |
||||
Repayments of convertible bonds |
|
|
|
– |
|
-500 |
|
-500 |
||||
Dividends paid |
|
|
|
-684 |
|
– |
|
– |
||||
Change in noncontrolling interests, net |
|
30 |
|
-6 |
|
-13 |
|
-13 |
||||
Net cash used in financing activities – continuing operations |
|
|
|
-2,423 |
|
-2,189 |
|
-2,134 |
||||
Net cash provided by/used in financing activities – discontinued operations |
|
|
|
– |
|
6 |
|
-49 |
||||
Net cash used in financing activities |
|
|
|
-2,423 |
|
-2,183 |
|
-2,183 |
||||
Effect of exchange rate changes on cash and cash equivalents |
|
|
|
-33 |
|
-2 |
|
-2 |
||||
Net decrease in cash and cash equivalents |
|
|
|
-697 |
|
-248 |
|
-248 |
||||
Cash and cash equivalents at the beginning of the reporting period |
|
15 |
|
2,282 |
|
2,562 |
|
2,562 |
||||
less cash and cash equivalents at the end of the reporting period |
|
|
|
– |
|
32 |
|
32 |
||||
Cash and cash equivalents at the end of the reporting period |
|
15 |
|
1,585 |
|
2,282 |
|
2,282 |
||||
|
||||||||||||
Additional information on payments that are included in net cash provided by operating activities – continuing operations
January 1 to December 31, € in millions |
|
|
2025 |
|
2024 restated1 |
|
2024 previous |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Received interest |
|
|
|
68 |
|
71 |
|
72 |
||||||
Paid interest |
|
|
|
-368 |
|
-415 |
|
-415 |
||||||
Income taxes paid |
|
|
|
-463 |
|
-430 |
|
-430 |
||||||
|
||||||||||||||